Orliday 120 Capsule contains Orlistat 120 mg, a potent lipase inhibitor indicated for the management of obesity. Orlistat acts locally in the gastrointestinal tract by selectively inhibiting pancreatic and gastric lipases, enzymes responsible for the hydrolysis of dietary triglycerides into absorbable free fatty acids and monoglycerides. By preventing the breakdown and subsequent absorption of approximately 30% of dietary fat, Orliday 120 facilitates weight reduction in conjunction with a reduced-calorie diet. It is prescribed for adults with a body mass index (BMI) ≥30 kg/m² or ≥27 kg/m² in the presence of other risk factors such as hypertension, diabetes mellitus, or dyslipidemia. Clinical studies demonstrate that Orlistat 120 mg, when combined with lifestyle modifications, significantly improves weight loss outcomes and reduces the risk of obesity-related comorbidities. The recommended dosage is one capsule taken orally three times daily with each main meal containing fat. Common adverse effects include gastrointestinal disturbances such as oily spotting, flatulence with discharge, and fecal urgency, which are generally mild and related to fat intake. Patients should adhere to a nutritionally balanced, reduced-calorie diet containing approximately 30% of calories from fat to minimize side effects and ensure optimal efficacy. Orliday 120 is contraindicated in patients with chronic malabsorption syndrome or cholestasis.